| 1350 |
National Cancer Institute |
Html |
en |
Adult Central Nervous System Tumors Treatment (PDQ®)–Patient Version |
Expert-reviewed information summary about the treatment of adult central nervous system tumors. |
| treatment | 0.515559 |
| malignant tumor cells | 0.227722 |
| general information | 0.262069 |
| NCI-supported cancer | 0.222651 |
| cancer cells | 0.27674 |
| type | 0.244277 |
| spinal cord tumors | 0.473603 |
| clinical trial search | 0.391071 |
| brain tumors | 0.2801 |
| spinal cord | 0.914442 |
| tumor cells | 0.493038 |
| normal cells | 0.296092 |
|
| clinical trial | 0.432056 |
| clinical trials | 0.701078 |
| brain tumor | 0.235359 |
| brain | 0.738045 |
| PDQ summary | 0.285532 |
| tumors | 0.535252 |
| cancer clinical trials | 0.361596 |
| tumor | 0.77091 |
| radiation therapy | 0.479169 |
| grade | 0.218633 |
| cancer | 0.578346 |
| information | 0.296506 |
|
CLICK HERE |
| 1473 |
National Cancer Institute |
Html |
en |
Gallbladder Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of gallbladder cancer. |
| similar median OS | 0.628591 |
| intact organ function | 0.622839 |
| PDQ cancer information | 0.730699 |
| extrahepatic bile duct | 0.642047 |
| standard surgical procedure | 0.635592 |
| Systemic chemotherapy | 0.571595 |
| lymphatic tissue | 0.570673 |
| biliary obstruction | 0.585733 |
| cancer information summary | 0.709899 |
| breast cancer prevention | 0.628762 |
| hematologic toxic effects | 0.620759 |
| delayed recurrences | 0.576123 |
| gallbladder cancer. | 0.68322 |
| median overall survival | 0.632156 |
| surgical specimen | 0.573532 |
| wedge resection | 0.601072 |
| liver tissue | 0.572719 |
| port sites | 0.635991 |
| single institution | 0.570884 |
| metastatic gallbladder cancer | 0.742217 |
| NCI’s PDQ | 0.589794 |
| NCI PDQ cancer | 0.658789 |
| lymph nodes | 0.686365 |
| consecutive surgical patients | 0.660543 |
|
| laparoscopic removal | 0.566309 |
| N2 lymph node | 0.694743 |
| gallbladder cancer | 0.941749 |
| transhepatic biliary drainage | 0.640041 |
| node positive tumors | 0.650245 |
| single-agent gemcitabine | 0.568199 |
| hepatoduodenal ligament | 0.573622 |
| surgical intervention. | 0.574213 |
| muscle layer | 0.568687 |
| routine gallbladder operation | 0.744072 |
| unsuspected cancer | 0.606476 |
| phase III study | 0.612031 |
| 5-year survival | 0.582018 |
| advanced biliary cancers | 0.636965 |
| PDQ documents | 0.58963 |
| platinum agents | 0.566154 |
| gallbladder bed | 0.684231 |
| transient partial remissions | 0.621529 |
| node negative tumors | 0.647847 |
| adequate performance status | 0.625607 |
| unsuspected gallbladder cancer | 0.785275 |
| Long-term disease-free survival | 0.641402 |
| pathologic examination | 0.580848 |
| Kaplan-Meier estimates | 0.57231 |
|
CLICK HERE |
| 1754 |
National Cancer Institute |
Html |
en |
Breast Reconstruction After Mastectomy |
A fact sheet that describes breast reconstruction after mastectomy, including surgical options, follow-up care, and breast cancer screening after reconstruction. |
| breast reduction surgery | 0.28849 |
| tissue breast reconstruction | 0.452019 |
| flap reconstruction | 0.330223 |
| immediate reconstruction | 0.31662 |
| tissue | 0.60196 |
| breast reconstruction surgery | 0.457163 |
| mastectomy | 0.359177 |
| implant | 0.307847 |
| implant reconstruction | 0.254395 |
| breast numbness | 0.249047 |
| donor tissue | 0.258639 |
| breast skin | 0.288491 |
| early-stage breast cancer | 0.279638 |
| natural breast shape | 0.273514 |
| pedicled flap reconstruction | 0.298564 |
| autologous tissue reconstruction | 0.366797 |
| breast cancer experience | 0.279508 |
| reconstructed breast | 0.419512 |
| autologous reconstruction | 0.246473 |
| tissue expander | 0.25279 |
| blood vessels | 0.426971 |
| chest wall tissue | 0.239092 |
| entire breast | 0.302278 |
| Delayed reconstruction | 0.247408 |
| breast cancer therapy | 0.323533 |
|
| radiation therapy | 0.283075 |
| breast reconstruction technique | 0.360333 |
| breast forms | 0.256638 |
| external breast prostheses | 0.334034 |
| women | 0.280496 |
| surgical nipple reconstruction | 0.280177 |
| breast reconstruction method | 0.374498 |
| breast reconstruction | 0.909174 |
| breast rebuilt | 0.281588 |
| free flap reconstruction | 0.325097 |
| breast cancer recurrence | 0.30156 |
| woman considering breast | 0.279422 |
| breast tissue | 0.318522 |
| flap | 0.344123 |
| sufficient breast volume | 0.289888 |
| autologous tissue | 0.583784 |
| Breast Implants page | 0.303495 |
| breast surgeons | 0.246995 |
| breast area | 0.280597 |
| breast cancer | 0.510147 |
| skin-sparing mastectomy | 0.235094 |
| Breast Disease | 0.251106 |
| inflammatory breast cancer | 0.289892 |
| chest tissue | 0.237416 |
|
CLICK HERE |
| 1763 |
National Cancer Institute |
Html |
en |
Anal Cancer Prevention (PDQ®)–Health Professional Version |
Expert-reviewed information summary about factors that may influence the risk of developing anal cancer and about research aimed at the prevention of this disease. |
| HPV status | 0.37901 |
| high-grade AIN | 0.400535 |
| HIV-positive men | 0.374588 |
| persistent HPV-6 | 0.369098 |
| receptive anal intercourse | 0.461565 |
| Squamous cell cancer | 0.399212 |
| vulvar cancer survivors | 0.380555 |
| anal cancer SIR | 0.523735 |
| situ cervical cancer | 0.423387 |
| vaccine efficacy | 0.403995 |
| invasive vulvar cancer | 0.380408 |
| anal cancer risk | 0.726451 |
| anal exposure | 0.434477 |
| control-arm participants | 0.42062 |
| invasive cervical cancer | 0.389499 |
| anal cancers | 0.477855 |
| anal cancer diagnosis | 0.502826 |
| aforementioned multicountry cohort | 0.36576 |
| anal specimen | 0.431502 |
| anal cancer development | 0.479231 |
| HIV-positive MSM | 0.39967 |
| HIV-positive individuals | 0.372051 |
| baseline HPV status | 0.371352 |
| Anal HPV infection | 0.502008 |
|
| cell anal cancer | 0.613468 |
| per-protocol analysis | 0.375594 |
| cervical cancer survivors | 0.388113 |
| invasive cervical cancer. | 0.365873 |
| CI | 0.564521 |
| anal intraepithelial neoplasia | 0.498397 |
| oncogenic HPV strains | 0.395201 |
| anal infection | 0.44494 |
| anal cancer | 0.940209 |
| incidence rate | 0.454386 |
| cervical cancer | 0.429644 |
| sexual practices | 0.401313 |
| intent-to-treat analysis | 0.37619 |
| anal specimens | 0.430195 |
| HPV vaccine regimen | 0.379059 |
| invasive vaginal cancer | 0.37973 |
| squamous cell anal | 0.539127 |
| high-grade squamous cell | 0.379806 |
| cervical cancer prevention | 0.379871 |
| standardized incidence ratio | 0.365263 |
| unprotected anal | 0.440711 |
| HIV infection | 0.421202 |
| HIV-positive women | 0.373444 |
|
CLICK HERE |
| 1781 |
National Cancer Institute |
Html |
es |
Aflicción, duelo y manejo de la pérdida (PDQ®)–Versión para profesionales de salud |
Informe revisado por expertos acerca de la aflicción, el duelo y los sentimientos de pérdida de los sobrevivientes de alguien que murió de cáncer. Se trata también la aflicción en los niños. |
| stage theory | 0.267105 |
| Maciejewski PK | 0.231481 |
| Stroebe MS | 0.59893 |
| Stroebe W | 0.357559 |
| Life after death | 0.262032 |
| recovery from bereavement | 0.268449 |
| practical approach | 0.234785 |
| Prigerson HG | 0.312593 |
| American Psychiatric | 0.266127 |
| querido experimentarán | 0.250079 |
| American Psychological Association | 0.813443 |
| anticipatory grief | 0.242932 |
| Basic Books | 0.301434 |
| doctors just suddenly | 0.262469 |
| expresión aflicción | 0.53581 |
| of bereavement | 0.95448 |
| Clin Psychol | 0.275517 |
| author reply | 0.229064 |
| Weiss RS | 0.256177 |
| OF BEREAVEMENT REACTIONS | 0.235244 |
| Abrahm J | 0.230792 |
| post-traumatic stress disorder | 0.252503 |
| normal grief | 0.23971 |
| Bonanno GA | 0.370739 |
| Rando TA | 0.231119 |
|
| aflicción crónica | 0.899606 |
| Psychol Rev | 0.235309 |
| hombres media | 0.239089 |
| aflicción —una estructura | 0.407961 |
| Kaltman S | 0.233673 |
| parkes cm | 0.351633 |
| Bowlby J | 0.229028 |
| stress disorder | 0.261132 |
| Publishing Company | 0.2876 |
| Kutner JS | 0.233996 |
| grief therapy | 0.242395 |
| Zisook S | 0.24705 |
| New York | 0.577019 |
| Pathologic Grief | 0.292395 |
| Intern Med | 0.234619 |
| Hansson RO | 0.641388 |
| Clin Psychiatry | 0.231444 |
| Volume III | 0.230537 |
| querido experimentarán perÃodos | 0.229309 |
| Springer Publishing Company | 0.252277 |
| BEREAVEMENT AND MENTAL | 0.237671 |
| Schut H | 0.386829 |
| Jacobs SC | 0.300142 |
| Casarett D | 0.230099 |
|
CLICK HERE |
| 2030 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud |
Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de mama. |
| carcinoma in situ | 0.428206 |
| Surgical Adjuvant Breast | 0.33856 |
| Breast Screening Study-2 | 0.364743 |
| cohort with breast | 0.321173 |
| Breast Cancer Surveillance | 0.36101 |
| American Cancer Society | 0.380459 |
| ductal proliferative breast | 0.324288 |
| ductal carcinoma in | 0.430875 |
| breast biopsy | 0.352636 |
| Elmore JG | 0.344418 |
| Swedish two-county breast | 0.320934 |
| Breast Screening | 0.503535 |
| Breast Screening Study | 0.375642 |
| Rosenberg RD | 0.33024 |
| Kerlikowske K | 0.327142 |
| Nelson HD | 0.325559 |
| Canadian National Breast | 0.417726 |
| Individual Breast Biopsy | 0.343511 |
| evaluación bi-rads | 0.320008 |
| Scotia Breast Screening | 0.356932 |
| breast pathology | 0.332437 |
| Estados Unidos | 0.485991 |
| screening mammograms | 0.346351 |
| Natl Cancer Inst | 0.674282 |
| Breast tumor characteristics | 0.346186 |
|
| mamografÃa detecta | 0.320239 |
| breast self-examination | 0.321577 |
| screening mammographic sensitivity | 0.338051 |
| National Breast Screening | 0.456899 |
| mamografÃa digital versus | 0.325297 |
| Breast Screening Program | 0.356597 |
| modern screening mammography | 0.338726 |
| Cancer Facts | 0.328174 |
| breast cancers | 0.931042 |
| Image-detected breast | 0.320721 |
| Breast Imaging Reporting | 0.320397 |
| screening mammography | 0.509779 |
| Breast Biopsy Slides | 0.344265 |
| screening trial | 0.341724 |
| mammographic screening | 0.329483 |
| Carney PA | 0.325142 |
| Intern Med | 0.487403 |
| Breast symptoms among | 0.322392 |
| Arch Intern Med | 0.323503 |
| clinical breast | 0.339712 |
| mammographic screening from | 0.319885 |
| in situ | 0.62536 |
| Cancer Surveillance Consortium | 0.332496 |
| Nova Scotia Breast | 0.339428 |
|
CLICK HERE |
| 15487 |
National Cancer Institute |
Html |
en |
Seeking Cancer Clues in Blood, Researchers Explore Exosomes |
A feature-length Research Update article about exploring ways to use vesicles known as exosomes to develop new clinical tests and tools for patients with cancer. |
| Dr. Alvarez | 0.382039 |
| exciting preliminary study | 0.288255 |
| Hector Alvarez | 0.230222 |
| organ-specific metastases | 0.263438 |
| research | 0.34419 |
| unneeded proteins | 0.218149 |
| cancer-associated genetic alterations | 0.292328 |
| Ph.D. | 0.232319 |
| reliable diagnostic biomarkers | 0.286894 |
| pancreatic tumors | 0.316162 |
| tumor-derived exosomes | 0.435098 |
| liver metastases | 0.261607 |
| distant sites | 0.270026 |
| David Lyden | 0.230954 |
| potential source | 0.27056 |
| potentially debilitating surgery | 0.288289 |
| researchers | 0.33374 |
| exosomal DNA | 0.235697 |
| generally reliable source | 0.276449 |
| ultimate goal | 0.288377 |
| liquid biopsy tests | 0.276523 |
| Dr. Lyden | 0.452577 |
| cell-free DNA | 0.302958 |
| Weill Cornell Medicine | 0.277332 |
| coauthor Bruno Costa-Silva | 0.277568 |
|
| different cells | 0.270221 |
| exosome-derived DNA | 0.320829 |
| potential clinical application | 0.294125 |
| primary cancer | 0.228119 |
| lung metastases | 0.261657 |
| cancer cells | 0.736815 |
| accompanying editorial | 0.30439 |
| Trinity College Dublin | 0.290697 |
| primary tumor cells | 0.384123 |
| release exosomes | 0.30546 |
| originating cells | 0.294925 |
| high-quality DNA | 0.233017 |
| metastases | 0.284855 |
| distant locations | 0.221908 |
| diagnostic blood test | 0.298912 |
| exosomes | 0.914671 |
| Cancer Research | 0.263148 |
| pancreatic cancer cells | 0.436342 |
| specific cells | 0.275707 |
| MD Anderson Cancer | 0.353274 |
| clinical tools | 0.317657 |
| breast cancer | 0.228037 |
| genetic changes | 0.218672 |
| tumor DNA | 0.385381 |
|
CLICK HERE |
| 15650 |
National Cancer Institute |
Html |
en |
Step 2: Application Receipt & Assignment |
Information on the assignment numbers the Center for Scientific Review (CSR) creates once an application is submitted and other submission policies. |
| Application Type | 0.237536 |
| 100,228th application | 0.228911 |
| program director | 0.554123 |
| peer review process | 0.902016 |
| initial peer review | 0.326681 |
| Scientific Review | 0.216004 |
| new application | 0.239088 |
| specific application | 0.226573 |
| Resubmission Applications | 0.206964 |
| research grant applications | 0.359218 |
| his/her assigned application | 0.489157 |
| specific budgetary limits | 0.31822 |
| Program Announcements | 0.201839 |
|
| pre-announced Request | 0.201939 |
| appropriate application form | 0.353459 |
| new grant | 0.218872 |
| NIH peer review | 0.369648 |
| Incomplete applications | 0.208003 |
| NCI program director | 0.428336 |
| suffix code | 0.378185 |
| grant numbers | 0.228139 |
| application | 0.702093 |
| NIH Policy | 0.353037 |
| traditional research project | 0.330544 |
| central receipt point | 0.406816 |
|
CLICK HERE |
| 16830 |
National Cancer Institute |
Html |
en |
Clinical Trial Sequencing Project |
null |
| gene expression test | 0.968523 |
| vital genomic information | 0.445867 |
| non-metastatic RCC | 0.377128 |
| breast cancer response | 0.478667 |
| Large B Cell | 0.384272 |
| NCTN clinical trials | 0.448807 |
| ECOG-ACRIN E2805 trial | 0.421922 |
| DLBCL patients | 0.352651 |
| National Clinical Trials | 0.46574 |
| molecular basis | 0.431838 |
| advanced RCC | 0.374566 |
| clinical trials | 0.533121 |
| VEGF inhibitors | 0.375945 |
| clinical trial | 0.642586 |
| RCC development | 0.370697 |
| breast cancer patients | 0.519364 |
| comprehensive molecular analysis | 0.404401 |
| Genomic Data Commons | 0.460933 |
| Trial Assigning Individualized | 0.463121 |
| cancer types | 0.360865 |
| surgical removal | 0.412464 |
| chemotherapy best complements | 0.471441 |
| large B-cell lymphoma | 0.45172 |
| cancer recurrence | 0.405985 |
| low-risk patients | 0.363667 |
|
| clinically helpful tool | 0.4004 |
| rich molecular data | 0.400698 |
| Combination Chemotherapy | 0.375651 |
| cancer research community | 0.644574 |
| adult non-Hodgkin lymphoma | 0.414301 |
| Her2-negative breast cancer | 0.645596 |
| NCI-sponsored clinical trial | 0.620071 |
| common kidney cancer | 0.437411 |
| endothelial growth factor | 0.403689 |
| different chemotherapy regimens | 0.474741 |
| human epidermal growth | 0.418539 |
| anonymized clinical data | 0.446701 |
| genomic alterations | 0.360205 |
| CCG | 0.375478 |
| NCI-sponsored clinical trials | 0.472546 |
| pathway drives RCC | 0.461359 |
| breast cancer | 0.780189 |
| best individualized treatment | 0.43596 |
| Clinical Trial Sequencing | 0.508554 |
| tissue samples | 0.518757 |
| breast cancer treatments | 0.478341 |
| renal cell carcinoma | 0.625007 |
| New England Journal | 0.405702 |
| Diffuse Large | 0.405055 |
|
CLICK HERE |
| 17285 |
National Cancer Institute |
Html |
en |
Cognitive Impairment in Adults with Non?Central Nervous System Cancers (PDQ®)–Health Professional Version |
Expert-reviewed information summary about cognitive impairment in cancer patients versus normal cognition, and interventions to manage cognition changes |
| baseline cognitive reserve | 0.507261 |
| Cognitive changes | 0.487133 |
| adjuvant chemotherapy | 0.565287 |
| cancer treatment | 0.487264 |
| female breast cancer | 0.505802 |
| healthy control subjects | 0.489493 |
| Evidence-based cognitive rehabilitation | 0.50091 |
| Primary Breast Cancer | 0.514885 |
| Advanced cognitive training | 0.507364 |
| Clin Breast Cancer | 0.579754 |
| cognitive disturbance | 0.483538 |
| therapy-related cognitive deficits | 0.504332 |
| Eur J Cancer | 0.484911 |
| early-stage breast cancer | 0.528107 |
| cognitive dysfunction | 0.521546 |
| Von Ah | 0.50591 |
| cognitive function | 0.609612 |
| cancer-related cognitive impairment | 0.500166 |
| cognitive problems. | 0.495567 |
| breast cancer patients | 0.582272 |
| cancer patients | 0.586019 |
| elderly cancer patients | 0.495074 |
| cognitive functioning | 0.510209 |
| breast cancer survivors | 0.779751 |
| self-reported cognitive complaints | 0.520137 |
|
| cancer survivors | 0.787075 |
| cancer chemotherapy | 0.497699 |
| et al. | 0.681052 |
| psychosocial cancer rehabilitation | 0.489752 |
| colorectal cancer survivors | 0.495325 |
| cognitive rehabilitation | 0.534264 |
| PUBMED Abstract | 0.565725 |
| Support Care Cancer | 0.521007 |
| chemotherapy-treated breast cancer | 0.517795 |
| self-reported cognitive dysfunction | 0.498525 |
| experience cognitive problems | 0.520232 |
| cognitive impairment. | 0.494247 |
| Abstract | 0.636513 |
| Clin Oncol | 0.48687 |
| breast cancer | 0.95028 |
| group cognitive rehabilitation | 0.514826 |
| elderly cancer survivors | 0.500464 |
| randomized controlled trial | 0.590229 |
| Cognitive rehabilitation group | 0.513937 |
| treatment-related cognitive impairment | 0.499304 |
| brain tumor patients | 0.525127 |
| chemotherapy-related cognitive change | 0.538912 |
| cognitive impairment | 0.555272 |
| self-reported cognitive problems | 0.505428 |
|
CLICK HERE |